The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society

Carroll, Christie L.; Balkrishnan, Rajesh; Feldman, Steven R.; Fleischer, Alan B.; Manuel, Janeen

doi:10.1111/j.1525-1470.2005.22303.x

Cited by 414 publications

(442 citation statements)

References 67 publications

(73 reference statements)

Supporting

Mentioning

415

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] It is a disease with a high and variable prevalence, [4][5][6][7][8][9][10][11] and there is evidence that the prevalence has increased in recent decades. 12,13 An association between childhood atopic eczema and asthma has been shown in at least 1 cross-sectional study 14 and in several longitudinal studies.…”

mentioning

confidence: 99%

Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age

Burgess¹,

Dharmage²,

Byrnes³

et al. 2008

Journal of Allergy and Clinical Immunology

101

View full text Add to dashboard Cite

mentioning

confidence: 99%

Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age

Burgess¹,

Dharmage²,

Byrnes³

et al. 2008

Journal of Allergy and Clinical Immunology

101

View full text Add to dashboard Cite

“…Ancak son çalışmalar göstermiştir ki deri hastalıkları yalnızca hastanın yaşamını değil hasta yakınlarının yaşamını da pek çok açıdan (ruhsal, fiziksel, sosyal, maddi) etkilemektedir 9,10 . Bireylerin yaşam kalitesi aynı ortamı paylaşan ya da bakım fonksiyonunu üstlenen kişilerin yaşam kalitesi ile yakından bağlantılıdır ve bazı durumlarda aile üyesinin yaşam kalitesi hastanın yaşam kalitesinden çok daha fazla bozulabilmektedir 3.11 .…”

Section: Discussionunclassified

“…Bakım fonksiyonunu üstlenen aile üyeleri fiziksel ve zihinsel yorgunluk, sosyal kopma ve maddi sorunlar gibi büyük etkilere maruz kalabilirler 3 . Bir hastanın deri hastalığının ailesi üzerine etkisi az sayıdaki dermatolojik durumda çalışılmıştır ve en çok ilgiyi atopik dermatit çekmiştir 9,[12][13][14][15][16][17] . Atopik dermatitli çocukların ebeveynleri için pek çok hastalığa özgü ölçek geliştirilmiştir 18,20 .…”

Section: Discussionunclassified

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Turan¹,

Gürel²,

Erdemir³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Background and Design: Skin diseases have negative impacts on patients' psychological well being, social life and daily activities. Close family members are also indirectly or directly affected with respect to care and treatment of patients. In particular, chronic skin diseases reduce the quality of life of family members who have close relationship with the patient. This study is aimed to determine how family members of patients are affected and to develop and validate a specific instrument for the Turkish population in order to use for measuring the impact of dermatological diseases. Materials and Methods: The Dermatological Diseases Family Impact Scale (DeFIS) has been prepared on the basis of data obtained from 176 family members of patients and the DeFIS was filled by close family members of 202 patients with chronic dermatosis aged between 18 and 76 years. The family members also responded to the General Health Questionnaire-12 (GHQ-12), whereas patients responded to the Turkish dermatology quality of life instrument (TDQL). Additionally, 202 healthy participants comprised a control group that responded to the DeFIS and GHQ-12. Disease severity was assessed by physicians and relatives of patients on the 5-point Likert scale. The DeFIS was developed into its final form based on the feedback received from family members of patients, dermatologists and psychologists. Psychometric evaluation was done for family members of patients who responded to the DeFIS and GHQ-12 as well as for patients who responded to the TDQL.

show abstract

“…48 In addition, cost-effectiveness studieso nd ifferent treatmentr egimensc an be recommendedt od ecreaset he economic impact of AD on society.…”

Section: Limitationsmentioning

confidence: 99%

Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis - Analysis of Administrative Claims

Suh¹,

Sung²,

Gause³

et al. 2007

JMCP

View full text Add to dashboard Cite

BACKGROUND: Atopic dermatitis (AD) has been associated with atopic manifestations (AMs), such as food allergies, asthma, allergic rhinitis, and allergic conjunctivitis.OBJECTIVES: To (1) compare the risk of developing AMs in patients with AD versus those without AD, (2) estimate the incremental costs attributable to AMs in patients with AD, and (3) examine the factors associated with incremental costs.METHODS: In this retrospective cohort study, the authors used MarketScan research databases containing medical and pharmacy claims with dates of service from January 1, 1999, to December 31, 2004. Patients were considered to have AD if they had at least 1 medical claim with a primary or secondary diagnosis of AD (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 691.8x) or contact dermatitis or other eczema of unspecified cause (ICD-9-CM codes 692.9x). To create comparable study cohorts, patients with AD were matched with non-AD patients using propensity scores that represented the likelihood of developing AD as predicted by logistic regression. After propensity score matching, the AD and non-AD cohorts did not statistically differ with respect to age, gender, geographic region, type of health insurance, Charlson Comorbidity Index, or baseline measures of medical and prescription drug utilization. The relative risks of developing AMs in the AD and non-AD cohorts were estimated using competing risk-survival analysis. AM was defined by ICD-9-CM codes for asthma (493.xx), allergic rhinitis (477.xx), allergic conjunctivitis (372.05 or 372.14), and food allergy (693.1x, 692.5x, 995.60). The annual incremental cost attributable to AMs in these AD patients was calculated from medical claims with AM and AD diagnosis codes and from pharmacy claims for prescription drugs used to treat asthma, allergic rhinitis, allergic conjunctivitis, or food allergy, and 95% confidence intervals (CIs) were calculated using the bootstrap method.RESULTS: Patients with AD were significantly more likely to develop AMs than patients without AD (21.8% versus 16.9%, adjusted relative risk [RR] = 1.33, 95% CI, 1.28-1.38). Among AD patients who developed AMs, allergic rhinitis was the most frequent manifestation (66.3%), followed by asthma (24.8%), allergic conjunctivitis (7.6%), and food allergy (1.8%). The incidence and adjusted RRs of developing AM for AD patients versus comparison patients were 5.3% versus 4.5% for asthma (RR = 1.20, 95% CI, 1.12-1.29), 14.6% versus 11.2% for allergic rhinitis (RR = 1.35, 95% CI, 1.29-1.41), 1.6% versus 1.1% for allergic conjunctivitis (RR = 1.50, 95% CI, 1.31-1.72), and 0.3% versus 0.1% for food allergy (RR = 2.35, 95% CI, 1.66-3.32). The annual AD + AM treatment costs for patients with AD increased substantially after they developed AMs. The additional financial burden attributable to AMs was estimated to be $482 per year, an almost 1.5-fold increase compared with AD cost alone (from $338 before AM development to $820 afterward, P < 0.001), with approxima...

show abstract

The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society

Cited by 414 publications

References 67 publications

Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age

Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis - Analysis of Administrative Claims

Contact Info

Product

Resources

About